US · SNGX · BIOTECHNOLOGY
Soligenix, Inc. (SNGX) intrinsic value and stock valuation
$0.22as of 2026-11-21 · Mkt cap 5.81M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Soligenix, Inc. DCF and intrinsic value
InvestorsCraft values SNGX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SNGX’s statements →
Soligenix, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $250K | $30K |
| Operating income | -$-11.85M | -$-9.44M | -$-7.7M | -$-14.24M | -$-13.1M |
| Net income | -$-11.08M | -$-8.27M | -$-6.14M | -$-13.8M | -$-12.55M |
| EPSd | -$-2.13M | -$-4.98M | -$-12.79M | -$-76.67M | -$-66.05M |
| Operating cash flow | -$-10.27M | -$-8.4M | -$-8.6M | -$-12.65M | -$-11.74M |
| Capital expenditure | -$-10K | $0.00 | $0.00 | -$-10K | -$-10K |
| Free cash flow | -$-10.27M | -$-8.4M | -$-8.6M | -$-12.66M | -$-11.75M |
| Total assets | $9.24M | $8.97M | $9.8M | $14.3M | $26.9M |
| Total debt | $360K | $1.48M | $3.49M | $10.2M | $9.96M |
| Net debt | -$-7.58M | -$-6.33M | -$-4.95M | -$-3.12M | -$-16.08M |
| Total equity | $5.29M | $4.12M | $2.52M | -$-2.47M | $10.7M |
| Cash and short-term investments | $7.94M | $7.82M | $8.45M | $13.4M | $26M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $250K | $30K |
| Cost of revenue | $0.00 | $120K | $740K | $550K | $730K |
| Gross profit | $0.00 | -$-120K | -$-740K | -$-300K | -$-700K |
| Research and development expenses | $7.49M | $5.22M | $3.31M | $7.94M | $8.19M |
| Selling, general and administrative expenses | $4.36M | $4.22M | $4.48M | $6.69M | $5.01M |
| Other expenses | $0.00 | -$-120K | -$-840K | -$-700K | -$-790K |
| Operating expenses | $11.9M | $9.32M | $6.96M | $13.9M | $12.4M |
| Cost and expenses | $11.9M | $9.44M | $7.7M | $14.5M | $13.1M |
| Interest income | $270K | $210K | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $50K | $820K | $900K |
| Depreciation and amortization | $0.00 | $10K | $10K | $20K | $30K |
| Ebitda | -$-11.58M | -$-9.46M | -$-7.67M | -$-14.11M | -$-12.48M |
| Operating income | -$-11.85M | -$-9.44M | -$-7.7M | -$-14.24M | -$-13.1M |
| Total other income/expenses, net | $260K | $760K | -$-210K | -$-710K | -$-320K |
| Income before tax | -$-11.59M | -$-8.68M | -$-7.91M | -$-14.95M | -$-13.42M |
| Income tax expense | -$-510K | -$-410K | -$-1.77M | -$-1.15M | -$-860K |
| Net income | -$-11.08M | -$-8.27M | -$-6.14M | -$-13.8M | -$-12.55M |
| Weighted average shares outstanding | $5.19M | $1.66M | $480K | $180K | $190K |
| Weighted average diluted shares outstanding | $5.19M | $1.66M | $480K | $180K | $190K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $7.94M | $7.82M | $8.45M | $13.4M | $26M |
| Net receivables | $0.00 | $0.00 | $200K | $220K | $240K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $8.85M | $8.83M | $9.51M | $13.9M | $26.6M |
| Property, plant and equipment, net | $350K | $120K | $240K | $360K | $130K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $390K | $140K | $290K | $430K | $300K |
| Total assets | $9.24M | $8.97M | $9.8M | $14.3M | $26.9M |
| Accounts payable | $1.12M | $670K | $1.11M | $3.87M | $2.93M |
| Short-term debt | $110K | $1.48M | $2.37M | $10M | $110K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $3.7M | $4.85M | $6.15M | $16.5M | $6.29M |
| Long-term debt | $240K | $0.00 | $1.12M | $230K | $9.86M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $240K | $0.00 | $1.12M | $230K | $9.86M |
| Capital lease obligations | $360K | $110K | $230K | $340K | $110K |
| Total liabilities | $3.94M | $4.85M | $7.27M | $16.8M | $16.2M |
| Common stock | $10K | $0.00 | $10K | $0.00 | $0.00 |
| Retained earnings | -$-245.05M | -$-233.97M | -$-225.7M | -$-219.56M | -$-205.77M |
| Accumulated other comprehensive income (loss) | $50K | $50K | $20K | $20K | $40K |
| Total equity | $5.29M | $4.12M | $2.52M | -$-2.47M | $10.7M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $360K | $1.48M | $3.49M | $10.2M | $9.96M |
| Net debt | -$-7.58M | -$-6.33M | -$-4.95M | -$-3.12M | -$-16.08M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-11.08M | -$-8.27M | -$-6.14M | -$-13.8M | -$-12.55M |
| Depreciation and amortization | $0.00 | $10K | $10K | $20K | $30K |
| Stock-based compensation | $590K | $330K | $370K | $330K | $360K |
| Change in working capital | $30K | -$-350K | -$-3.44M | $430K | $650K |
| Accounts receivable | $0.00 | $220K | $30K | $20K | $60K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-1.13M |
| Accounts payable | -$-20K | -$-490K | -$-2.69M | $400K | $1.13M |
| Net cash provided by operating activities | -$-10.27M | -$-8.4M | -$-8.6M | -$-12.65M | -$-11.74M |
| Investments in property, plant and equipment | -$-10K | $0.00 | $0.00 | -$-10K | -$-10K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-10K | $0.00 | $0.00 | -$-10K | -$-10K |
| Common stock issued | $12.5M | $5.81M | $11.6M | $80K | $19.7M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $10.4M | $7.76M | $3.66M | $80K | $19.1M |
| Net change in cash | $120K | -$-630K | -$-4.91M | -$-12.68M | $7.37M |
| Cash at end of period | $7.94M | $7.82M | $8.45M | $13.4M | $26M |
| Operating cash flow | -$-10.27M | -$-8.4M | -$-8.6M | -$-12.65M | -$-11.74M |
| Capital expenditure | -$-10K | $0.00 | $0.00 | -$-10K | -$-10K |
| Free cash flow | -$-10.27M | -$-8.4M | -$-8.6M | -$-12.66M | -$-11.75M |
Line items
Line items
Line items
About Soligenix, Inc.
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
- CEO
- Christopher J. Schaber
- Employees
- 14
- Beta
- 1.92
Explore
Frequently asked questions
What is the intrinsic value of Soligenix, Inc. (SNGX)?
InvestorsCraft does not currently publish an intrinsic value for SNGX. How the IC value is calculated.
Is SNGX undervalued?
InvestorsCraft does not publish an undervaluation signal for SNGX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.